Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies.
We recently reported several driver genes of biliary tract carcinoma (BTC) that are known to play important roles in oncogenesis and disease progression. Although the need for developing novel therapeutic strategies is increasing, there are very few BTC cell lines and xenograft models currently available for conducting preclinical studies. Using a total of 88 surgical BTC specimens and 536 immunodeficient mice, 28 xenograft models and 13 new BTC cell lines, including subtypes, were established. Some of our cell lines were found to be resistant to gemcitabine, which is currently the first choice of treatment, thereby allowing highly practical preclinical studies to be conducted. Using the aforementioned cell lines and xenograft models and a clinical pathological database of patients undergoing BTC resection, we can establish a preclinical study system and appropriate parameters for drug efficacy studies to explore new biomarkers for practical applications in the future studies.
Hidenori Ojima, Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Hidenori
H
Ojima
Hidenori Ojima, Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Seri
S
Yamagishi
Hidenori Ojima, Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Kazuaki
K
Shimada
Hidenori Ojima, Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Tatsuhiro
T
Shibata
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001661:Biliary Tract Neoplasms / Q000473:pathology*; D002277:Carcinoma / Q000473:pathology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D023041:Xenograft Model Antitumor Assays
Biliary tract carcinoma; Cell line; Preclinical study; Xenograft model